Cervical Cancer Prevention in CEE and the NIS: The Way Forward. John Sellors, MD PATH (Program for Appropriate Technology in Health) Seattle, USA. Overview of Presentation. Global burden of disease Regional statistics and challenges Overview of screening technologies and programmatic issues
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
John Sellors, MD
PATH (Program for Appropriate Technology in Health)
Age standardized rates per 100,000 (based on world population)
(Sellors et al., CMAJ 2000)
Screening strategies are intended to identify these abnormalities.
**Koutsky et al., NEJM, ‘02
Barnabas and Garnett, ’02, unpublished
Fahey et al.
U. Harare/ JHPIEGO
Conventional Pap test is still the only screening test ‘proven’ to reduce incidence and mortality rates of ICC.
CIN is slow growing.
Many low-grade CINs regress.
Abnormalities missed by one screening will probably be detected in next interval.
ICC usually due to lack of screening rather than cytologic errors.
automated LBC sample prep system
~60,000 selected cells distributed in a thin layer
smaller area than conventional Pap
specimens read optically or digitally
*FDA approved for screening
As of Sept. 2001
AutoPap 300 (Tripath) and Trac Cell 2000 (Accumed International)
automated LBC sample prep
visual intelligence computer technology
sorts by probability of abnormality
*FDA approved only for mandatory rescreening
randomly selected cells in thin layer
better quality fixation and less ‘debris’
quicker reading - 3.2 min (double for Pap)
amenable to HPV testing and immunohistochem. for different antigens
more costly than Pap - worse compliance?
retraining needed for smear-takers and pathology lab
HC IITM (Digene, Inc) is the only FDA approved, commercially available test.
Sensitivity and specificity of HC II for the detection of CIN 2/3 infour specimen types
n=200, colposcopy clinic
Sellors et al, 2000
*for high grade disease
Sankaranarayanan et al, Int J Cancer 2004
Proportion of HC II positive specimens with viral levels above a cutoff (RLU > 15.0)
n=200, colposcopy clinic
CIN 3 includes CIS
‘Condyloma/HPV effect’ separated from CIN 1 (together had been ‘Mild Dysplasia’)
HSIL contains CIN 2 & 3
LSIL includes HPV
ASCUS distinct from atypia due to repair, reaction, infection